73963-62-9

Usage

Uses

Used in Pharmaceutical Applications:
6-[4-(1-CYCLOHEXYL-1H-TETRAZOL-5-YL) BUTOXY]-2(1H)-QUINOLINONE is used as an active metabolite for enhancing the therapeutic effects of Cilostazol. As a metabolite, it contributes to the overall pharmacological action of the parent drug, potentially improving its efficacy and safety profile in treating various medical conditions.
Used in Research and Development:
In the field of pharmaceutical research and development, 6-[4-(1-CYCLOHEXYL-1H-TETRAZOL-5-YL) BUTOXY]-2(1H)-QUINOLINONE serves as a valuable compound for studying the metabolic pathways of Cilostazol and understanding its pharmacological properties. This knowledge can be applied to the design and development of new drugs with improved efficacy and reduced side effects.
Used in Quality Control and Analysis:
6-[4-(1-CYCLOHEXYL-1H-TETRAZOL-5-YL) BUTOXY]-2(1H)-QUINOLINONE is also utilized in the quality control and analysis of Cilostazol-containing pharmaceutical products. Its presence can be detected and quantified to ensure the purity, potency, and consistency of the drug, contributing to patient safety and compliance with regulatory standards.

InChI:InChI=1/C20H25N5O2/c26-20-12-9-15-14-17(10-11-18(15)21-20)27-13-5-4-8-19-22-23-24-25(19)16-6-2-1-3-7-16/h9-12,14,16H,1-8,13H2,(H,21,26)

Upstream product

• 19315-93-6 6-hydroxy-1H-quinolin-2-one 
• 73963-42-5 1-cyclohexyl-5-(4-chlorobutyl)-1,2,3,4-tetrazole 
• 54197-66-9 3,4-dihydro-6-hydroxy-2(1H)-quinolinone 

Downstream Products

• 135498-81-6 <(cyclohexyl-1 tetrazolyl-5)-4 butoxy>-7 tetrazolo <1,5-a> quinoleine 
• 135498-80-5 <(cyclohexyl-1 tetrazolyl-5)-4 butoxy>-7 methyl-3 triazolo <4,3-a> quinoleine 
• 135498-79-2 <(cyclohexyl-1 tetrazolyl-5)-4 butoxy>-7 triazolo <4,3-a> quinoleine 
• 135498-82-7 <(cyclohexyl-1 tetrazolyl-5)-4 butoxy>-6 hydrazino-2 quinoleine 
• 135498-83-8 <(cyclohexyl-1 tetrazolyl-5)-4 butoxy>-6 chloro-2 quinoleine 

Relevant academic research and scientific papers

Synthesis of related substances of cilostazol

The impurities in API of cilostazol were detected by LC/MS during the process development. The structures of two impurities 6 and 7 and the related formation mechanisms were proposed. Synthesis of 6 and 7 was conducted for confirmation of the speculated structures.

PROCESS FOR PURIFICATION OF CILOSTAZOL

The present invention provides a process for preparing high purity cilostazol. The process comprises: (a) adding crude cilostazol to an acid selected from the group consisting of oxalic acid, maleic acid, sulfuric acid, and a mixture thereof to form a cilostazol salt; and (b) recovering cilostazol through adding a base to the cilostazol salt.

Studies on 2-oxoquinoline derivatives as blood platelet aggregation inhibitors. II. 6-[3-(1-Cyclohexyl-5-tetrazolyl)propoxy]-1,2-dihydro-2-oxoquinoline and related compounds

A series of ω-(1-substituted-5-tetrazolylalkoxy)-2-oxoquinolines was synthesized and tested for inhibitory activity towards collagen- and adenosine diphosphate (ADP)-induced aggregation of rabbit blood platelets in vitro. These compounds were prepared by the reaction of 1-substituted-5-(ω-chloroalkyl)-tetrazoles and hydroxy-2-oxoquinolines in the presence of a base. Among them, 6-[3-(1-cyclohexyl-5-tetrazolyl)propoxy]-1,2-dihydro-2-oxoquinoline (IVb) was found to have the most potent inhibitory activity. The structure-activity relationships are discussed.

TETRAZOLYLALKOXYCARBOSTYRIL DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM

Novel tetrazolylalkoxycarbostyril derivative of the formula (I).The above-mentioned novel tetrazolylalkoxycarbostyril derivatives have pharmacological activities such as platelet aggregation inhibitory action, antiinflammatory action, antiulcer action, vasodilatory action and phosphodiesterase inhibitory action and are useful as anti-thrombosis agent, cerebral blood flow improving agent, antiinflammatory agent, antiulcer agent, anti-hypertensive agent and anti-asthmatic agent